Aclaris Discontinued Operations vs Ebitda Analysis

ACRS Stock

USD 4.32 0.36 9.09%

Aclaris Therapeutics financial indicator trend analysis is way more than just evaluating Aclaris Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aclaris Therapeutics is a good investment. Please check the relationship between Aclaris Therapeutics Discontinued Operations and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

Discontinued Operations vs Ebitda

Discontinued Operations vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aclaris Therapeutics Discontinued Operations account and Ebitda. At this time, the significance of the direction appears to have no relationship.

The correlation between Aclaris Therapeutics' Discontinued Operations and Ebitda is 0.03. Overlapping area represents the amount of variation of Discontinued Operations that can explain the historical movement of Ebitda in the same time period over historical financial statements of Aclaris Therapeutics, assuming nothing else is changed. The correlation between historical values of Aclaris Therapeutics' Discontinued Operations and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Discontinued Operations of Aclaris Therapeutics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Discontinued Operations i.e., Aclaris Therapeutics' Discontinued Operations and Ebitda go up and down completely randomly.

Correlation Coefficient

0.03

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Discontinued Operations

Ebitda

Most indicators from Aclaris Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aclaris Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.Discontinued Operations is likely to gain to about 167.8 K in 2024, whereas Selling General Administrative is likely to drop slightly above 21.3 M in 2024.

Aclaris Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Non Currrent Assets Other	Other Assets	Deferred Long Term Liab	Long Term Investments
Total Assets		0.77	0.79	0.99	0.58	0.68	-0.48	-0.62	0.86	0.54	0.74	0.96	0.7	0.94	-0.04	0.71	0.79	0.51	0.78	0.97	0.28	0.97	-0.1	0.44	0.59	0.49
Other Current Liab	0.77		0.73	0.7	0.35	0.69	-0.22	-0.56	0.82	0.3	0.55	0.73	0.66	0.7	0.34	0.73	0.72	0.7	0.6	0.73	0.32	0.63	0.13	0.6	0.72	0.04
Total Current Liabilities	0.79	0.73		0.72	0.67	0.79	-0.24	-0.86	0.94	0.31	0.8	0.66	0.91	0.61	0.03	0.68	0.93	0.69	0.89	0.69	0.57	0.77	0.27	0.38	0.93	0.46
Total Stockholder Equity	0.99	0.7	0.72		0.52	0.64	-0.53	-0.56	0.79	0.58	0.68	0.97	0.64	0.95	-0.17	0.65	0.74	0.36	0.71	0.98	0.26	0.98	-0.19	0.39	0.51	0.5
Other Liab	0.58	0.35	0.67	0.52		0.22	-0.11	-0.9	0.53	0.12	0.61	0.55	0.82	0.54	0.04	0.72	0.8	0.55	0.9	0.55	0.08	0.62	0.24	0.29	0.51	0.79
Property Plant And Equipment Net	0.68	0.69	0.79	0.64	0.22		-0.37	-0.49	0.89	0.5	0.79	0.51	0.5	0.48	0.02	0.33	0.58	0.55	0.61	0.56	0.66	0.59	0.25	0.23	0.81	0.11
Net Debt	-0.48	-0.22	-0.24	-0.53	-0.11	-0.37		0.13	-0.34	-0.99	-0.23	-0.51	-0.21	-0.58	0.32	-0.16	-0.26	0.07	-0.21	-0.52	-0.26	-0.48	-0.06	0.07	-0.05	-0.14
Retained Earnings	-0.62	-0.56	-0.86	-0.56	-0.9	-0.49	0.13		-0.73	-0.17	-0.65	-0.56	-0.94	-0.52	0.01	-0.71	-0.93	-0.62	-0.92	-0.57	-0.42	-0.63	-0.31	-0.29	-0.8	-0.64
Accounts Payable	0.86	0.82	0.94	0.79	0.53	0.89	-0.34	-0.73		0.43	0.81	0.74	0.78	0.7	0.12	0.65	0.84	0.72	0.83	0.77	0.61	0.77	0.25	0.41	0.9	0.3
Cash	0.54	0.3	0.31	0.58	0.12	0.5	-0.99	-0.17	0.43		0.34	0.54	0.24	0.6	-0.28	0.17	0.3	0.01	0.27	0.55	0.29	0.52	0.09	-0.05	0.14	0.13
Non Current Assets Total	0.74	0.55	0.8	0.68	0.61	0.79	-0.23	-0.65	0.81	0.34		0.56	0.6	0.53	0.07	0.51	0.65	0.64	0.85	0.59	0.28	0.7	0.26	0.35	0.69	0.55
Cash And Short Term Investments	0.96	0.73	0.66	0.97	0.55	0.51	-0.51	-0.56	0.74	0.54	0.56		0.64	0.99	-0.08	0.73	0.74	0.39	0.69	1.0	0.21	0.93	-0.21	0.46	0.45	0.48
Common Stock Shares Outstanding	0.7	0.66	0.91	0.64	0.82	0.5	-0.21	-0.94	0.78	0.24	0.6	0.64		0.61	0.07	0.77	0.98	0.66	0.87	0.66	0.39	0.71	0.25	0.35	0.8	0.54
Short Term Investments	0.94	0.7	0.61	0.95	0.54	0.48	-0.58	-0.52	0.7	0.6	0.53	0.99	0.61		-0.08	0.73	0.7	0.35	0.66	0.98	0.18	0.91	-0.14	0.44	0.38	0.44
Non Current Liabilities Total	-0.04	0.34	0.03	-0.17	0.04	0.02	0.32	0.01	0.12	-0.28	0.07	-0.08	0.07	-0.08		0.26	0.0	0.72	0.08	-0.1	-0.27	-0.22	0.4	0.36	0.12	-0.38
Other Current Assets	0.71	0.73	0.68	0.65	0.72	0.33	-0.16	-0.71	0.65	0.17	0.51	0.73	0.77	0.73	0.26		0.79	0.64	0.73	0.7	0.15	0.66	0.24	0.82	0.55	0.45
Other Stockholder Equity	0.79	0.72	0.93	0.74	0.8	0.58	-0.26	-0.93	0.84	0.3	0.65	0.74	0.98	0.7	0.0	0.79		0.63	0.89	0.75	0.42	0.8	0.2	0.39	0.82	0.54
Total Liab	0.51	0.7	0.69	0.36	0.55	0.55	0.07	-0.62	0.72	0.01	0.64	0.39	0.66	0.35	0.72	0.64	0.63		0.71	0.39	0.19	0.36	0.49	0.49	0.71	0.12
Property Plant And Equipment Gross	0.78	0.6	0.89	0.71	0.9	0.61	-0.21	-0.92	0.83	0.27	0.85	0.69	0.87	0.66	0.08	0.73	0.89	0.71		0.7	0.35	0.76	0.29	0.36	0.77	0.67
Total Current Assets	0.97	0.73	0.69	0.98	0.55	0.56	-0.52	-0.57	0.77	0.55	0.59	1.0	0.66	0.98	-0.1	0.7	0.75	0.39	0.7		0.25	0.95	-0.21	0.41	0.48	0.48
Property Plant Equipment	0.28	0.32	0.57	0.26	0.08	0.66	-0.26	-0.42	0.61	0.29	0.28	0.21	0.39	0.18	-0.27	0.15	0.42	0.19	0.35	0.25		0.24	0.28	0.04	0.7	-0.01
Net Tangible Assets	0.97	0.63	0.77	0.98	0.62	0.59	-0.48	-0.63	0.77	0.52	0.7	0.93	0.71	0.91	-0.22	0.66	0.8	0.36	0.76	0.95	0.24		-0.19	0.35	0.53	0.62
Non Currrent Assets Other	-0.1	0.13	0.27	-0.19	0.24	0.25	-0.06	-0.31	0.25	0.09	0.26	-0.21	0.25	-0.14	0.4	0.24	0.2	0.49	0.29	-0.21	0.28	-0.19		0.17	0.39	-0.2
Other Assets	0.44	0.6	0.38	0.39	0.29	0.23	0.07	-0.29	0.41	-0.05	0.35	0.46	0.35	0.44	0.36	0.82	0.39	0.49	0.36	0.41	0.04	0.35	0.17		0.34	0.17
Deferred Long Term Liab	0.59	0.72	0.93	0.51	0.51	0.81	-0.05	-0.8	0.9	0.14	0.69	0.45	0.8	0.38	0.12	0.55	0.82	0.71	0.77	0.48	0.7	0.53	0.39	0.34		0.22
Long Term Investments	0.49	0.04	0.46	0.5	0.79	0.11	-0.14	-0.64	0.3	0.13	0.55	0.48	0.54	0.44	-0.38	0.45	0.54	0.12	0.67	0.48	-0.01	0.62	-0.2	0.17	0.22

Click cells to compare fundamentals

Aclaris Therapeutics Account Relationship Matchups

Aclaris Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	98.3M	70.8M	251.2M	254.6M	197.4M	169.3M
Other Current Liab	4.2M	8.4M	11.6M	10.2M	2.2M	2.1M
Total Current Liabilities	22.4M	14.9M	22.9M	21.9M	31.0M	16.3M
Total Stockholder Equity	69.9M	37.7M	197.3M	197.6M	157.2M	133.2M
Other Liab	2.4M	7.6M	28.8M	33.5M	38.5M	40.4M
Property Plant And Equipment Net	2.5M	1.7M	1.3M	1.1M	1.6M	1.6M
Net Debt	(35.3M)	(42.9M)	(26.7M)	(44.6M)	(39.5M)	(41.4M)
Retained Earnings	(453.5M)	(504.5M)	(595.4M)	(682.3M)	(770.8M)	(732.3M)
Accounts Payable	9.9M	5.3M	10.0M	10.4M	8.9M	7.2M
Cash	35.9M	54.1M	27.3M	45.3M	39.9M	52.9M
Non Current Assets Total	14.5M	13.3M	46.2M	23.0M	68.5M	72.0M
Cash And Short Term Investments	75.0M	54.1M	225.7M	229.8M	119.1M	137.6M
Common Stock Shares Outstanding	41.3M	42.5M	56.7M	65.2M	69.8M	38.5M
Short Term Investments	39.1M	32.1M	164.1M	172.3M	79.2M	96.3M
Liabilities And Stockholders Equity	98.3M	70.8M	251.2M	254.6M	197.4M	169.3M
Non Current Liabilities Total	6.0M	18.3M	30.9M	35.0M	9.3M	8.8M
Other Current Assets	3.1M	5.2M	26.0M	13.5M	9.5M	7.2M
Other Stockholder Equity	523.5M	542.3M	793.0M	880.8M	928.1M	495.6M
Total Liab	28.4M	33.1M	53.9M	57.0M	40.2M	36.1M
Property Plant And Equipment Gross	2.5M	1.7M	4.7M	5.1M	5.8M	6.1M
Total Current Assets	83.8M	57.5M	205.0M	231.6M	128.9M	139.1M
Accumulated Other Comprehensive Income	(66K)	(94K)	(224K)	(897K)	(106K)	(111.3K)
Property Plant Equipment	7.2M	1.7M	1.3M	1.1M	1.3M	1.9M
Net Tangible Assets	62.7M	30.5M	190.3M	190.6M	219.2M	135.0M
Non Currrent Assets Other	4.8M	4.5M	3.6M	(630K)	1.7M	1.8M
Other Assets	92K	4.5M	251.2M	1.7M	2.0M	1.9M
Net Receivables	704K	772K	623K	484K	298K	283.1K
Retained Earnings Total Equity	(453.5M)	(504.5M)	(595.4M)	(682.3M)	(614.1M)	(583.4M)
Capital Surpluse	523.5M	542.3M	793.0M	880.8M	1.0B	553.9M
Inventory	791K	5.0M	(34.2M)	(12.2M)	(11.0M)	(10.5M)
Intangible Assets	7.2M	7.1M	7.0M	7.0M	269K	255.6K
Non Current Liabilities Other	5.4M	7.2M	30.6M	34.7M	9.3M	13.1M
Short Long Term Debt Total	658K	11.3M	693K	684K	426K	404.7K
Capital Lease Obligations	637K	603K	693K	684K	426K	594.9K
Net Invested Capital	69.9M	48.3M	197.3M	197.6M	157.2M	130.4M
Net Working Capital	61.4M	42.6M	182.1M	209.6M	97.9M	106.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC